Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 3Neoplasms 3Leukemia, Myeloid, Acute 3Breast Neoplasms 3Pancreatic Neoplasms 2Neoplastic Cells, Circulating 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Myeloid 1Rectal Neoplasms 1Pruritus 1Polycystic Ovary Syndrome 1Papillomavirus Infections 1Pancreatic Adenocarcinoma 1Overweight 1Oropharyngeal Neoplasms 1Opioid-Related Disorders 1Obesity 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

devimistat 1Metformin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Sarcoma, Myeloid × Blood Specimen Collection × Clear all
NCT05854966 2024-09-19

CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Wake Forest University Health Sciences

Phase 2 Withdrawn
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡